Sequential Combination of Intravenous Recombinant Tissue Plasminogen Activator and Intra-Arterial Urokinase in Acute Ischemic Stroke

References

1. ↵
   The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group: tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995;333:1581–1587

   CrossRefPubMedWeb of Science
2. ↵
   del Zoppo GJ, Poeck K, Pessin MS, et al. Recombinant tissue plasminogen activator in acute thrombotic and embolic stroke. Ann Neurol 1992;32:78–86

   CrossRefPubMedWeb of Science
3. ↵
   Wolpert SM, Bruckmann H, Greenlee R, et al. Neuroradiologic evaluation of patients with acute stroke treated with recombinant tissue plasminogen activator. AJNR Am J Neuroradiol 1993;14:3–13

   Abstract/FREE Full Text
4. ↵
   del Zoppo GJ, Higashida RT, Furlan AJ, et al. PROACT: a phase II randomized trial of recombinant pro-urokinase by direct arterial delivery in acute middle cerebral artery stroke. Stroke 1998;29:4–11

   Abstract/FREE Full Text
5. ↵
   Furlan A, Higashida R, Wechsler L, et al. Intra-arterial prourokinase for acute ischemic stroke: the PROACT II study: a randomized controlled trial. JAMA 1999;282:2003–2011

   CrossRefPubMedWeb of Science
6. ↵
   Jahan R, Duckwiler GR, Kidwell CS, et al. Intraarterial thrombolysis for treatment of acute stroke: experience in 26 patients with long-term follow-up. AJNR Am J Neuroradiol 1999;20:1291–1299

   Abstract/FREE Full Text
7. ↵
   Lewandowski CA, Frankel M, Tomsick TA, et al. Combined intravenous and intra-arterial r-TPA versus intra-arterial therapy of acute ischemic stroke: Emergency Management of Stroke (EMS) Bridging Trial. Stroke 1999;30:2598–2605

   Abstract/FREE Full Text
8. ↵
   Ernst R, Pancioli A, Tomsick T, et al. Combined intravenous and intra-arterial recombinant tissue plasminogen activator in acute ischemic stroke. Stroke 2000;31:2552–2557

   Abstract/FREE Full Text
9. Keris V, Rudnicka S, Vorona V, Enina G, Tilgale B, Fricbergs J Combined intraarterial/intravenous thrombolysis for acute ischemic stroke. AJNR Am J Neuroradiol 2001;22:352–358

   Abstract/FREE Full Text
10. ↵
    Suarez JI, Zaidat OO, Sunshine JL, Tarr R, Selman WR, Landis DM. Endovascular administration after intravenous infusion of thrombolytic agents for the treatment of patients with acute ischemic strokes. Neurosurgery 2002;50:251–260

    CrossRefPubMedWeb of Science
11. ↵
    Hill MD, Barber PA, Demchuk AM, et al. Acute intravenous-intra-arterial revascularization therapy for severe ischemic stroke. Stroke 2002;33:279–282

    Abstract/FREE Full Text
12. ↵
    Maksimenko AV, Tischenko EG. New thrombolytic strategy: bolus administration of tPA and urokinase-fibrinogen conjugate. J Thromb Thrombolysis 1999;7:307–312

    PubMed
13. Popma JJ, Califf RM, Ellis SG, et al. Mechanism of benefit of combination thrombolytic therapy for acute myocardial infarction: a quantitative angiographic and hematologic study. J Am Coll Cardiol 1992;20:1305–1312

    PubMed
14. ↵
    Califf RM, Topol EJ, Stack RS, et al. Evaluation of combination thrombolytic therapy and timing of cardiac catheterization in acute myocardial infarction: results of thrombolysis and angioplasty in myocardial infarction - phase 5 randomized trial. Circulation 1991;83:1543–1556

    Abstract/FREE Full Text
15. Morris JA, Muller DW, Topol EJ. Combination thrombolytic therapy: a comparison of simultaneous and sequential regimens of tissue plasminogen activator and urokinase. Am Heart J 1991;122:375–380

    CrossRefPubMedWeb of Science
16. ↵
    Collen D, Stassen JM, De Cock F. Synergistic effect of thrombolysis of sequential infusion of tissue-type plasminogen activator (t-PA) single-chain urokinase-type plasminogen activator (scu-PA) and urokinase in the rabbit jugular vein thrombosis model. Thromb Haemost 1987;58:943–946

    PubMed
17. ↵
    Pannell R, Black J, Gurewich V. Complementary modes of action of tissue-type plasminogen activator and pro-urokinase by which their synergistic effect on clot lysis may be explained. J Clin Invest 1988;81:853–859
18. ↵
    The IMS Study Investigators. Combined intravenous and intra-arterial recanalization for acute ischemic stroke: the interventional management of stroke study. Stroke 2004;35:904–911

    Abstract/FREE Full Text
19. ↵
    Alexandrov AV, Grotta JC. Arterial reocclusion in stroke patients treated with intravenous tissue plasminogen activator. Neurology 2002;59:862–867

    Abstract/FREE Full Text
20. ↵
    Heo JH, Lee KY, Kim SH, Kim DI. Immediate reocclusion following a successful thrombolysis in acute stroke: a pilot study. Neurology 2003;60:1684–1687

    Abstract/FREE Full Text
21. Lee KY, Heo JH, Lee SI, Yoon PY. Rescue treatment with abciximab in acute ischemic stroke. Neurology 2001;56:1585–1587

    Abstract/FREE Full Text
22. Kwon OK, Lee KJ, Han MH, Oh CW, Han DH, Koh YC. Intraarterially administered abciximab as an adjuvant thrombolytic therapy: report of three cases. AJNR Am J Neuroradiol 2002;23:447–451

    Abstract/FREE Full Text
23. ↵
    Vivekananthan DP, Moliterno DJ. Glycoprotein IIb/IIIa combination therapy in acute myocardial infarction: tailoring therapies to optimize outcome. J Thromb Thrombolysis 2002;13:35–39

    PubMed
24. ↵
    AbESTT Investigators. Effect of abciximab for acute ischemic stroke: final results of abciximab in emergent stroke treatment trial (AbESTT). Stroke 2003;34:253
25. ↵
    Hacke W, Kaste M, Fieschi C, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke: the European Cooperative Acute Stroke Study (ECASS). JAMA 1995;274:1017–1025

    CrossRefPubMedWeb of Science
26. ↵
    Kidwell CS, Saver JL, Carneado J, et al. Predictors of hemorrhagic transformation in patients receiving intra-arterial thrombolysis. Stroke 2002;33:717–724

    Abstract/FREE Full Text
27. ↵
    Levy DE, Brott TG, Haley EC Jr, et al. Factors related to intracranial hematoma formation in patients receiving tissue-type plasminogen activator for acute ischemic stroke. Stroke 1994;25:291–297

    Abstract/FREE Full Text
28. ↵
    The NINDS t-PA Stroke Study Group. Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke. Stroke 1997;28:2109–2118

    Abstract/FREE Full Text
29. ↵
    Larrue V, von Kummer R, del Zoppo G, Bluhmki E. Hemorrhagic transformation in acute ischemic stroke: potential contributing factors in the European Cooperative Acute Stroke Study. Stroke 1997;28:957–960

    Abstract/FREE Full Text
30. ↵
    Heo JH, Lucero J, Abumiya T, Koziol JA, Copeland BR, del Zoppo GJ. Matrix metalloproteinases increase very early during experimental focal cerebral ischemia. J Cereb Blood Flow Metab 1999;19:624–633

    CrossRefPubMedWeb of Science
31. ↵
    Montaner J, Molina CA, Monasterio J, et al. Matrix metalloproteinase-9 pretreatment level predicts intracranial hemorrhagic complications after thrombolysis in human stroke. Circulation 2003;107:598–603

    Abstract/FREE Full Text
32. ↵
    Heo JH, Kim SH, Lee KY, Kim EH, Chu CK, Nam JM. Increase in plasma matrix metalloproteinase-9 in acute stroke patients with thrombolysis failure. Stroke 2003;34:48–50